Minimally invasive cancer treatment does not end when the ablation needle is withdrawn or the final embolisation session is completed. For patients, families and the clinicians who refer them, the decisive questions usually concern what happens next: which follow-up and rehabilitation steps are documented, what imaging and pathology deliverables are produced, how discharge plans and nursing records are handed over, and what a long-term referral relationship actually includes. This guide answers those questions in a practical, FAQ-driven format, and it states clearly where the source material documents a commitment and where it does not.

Nursing stations such as this one support the documented rehabilitation and follow-up stage of the treatment framework. Image: Guangzhou Fuda Cancer Hospital.

What Patients and Referrers Actually Need to Know After Treatment

The word “minimally” describes the access route, not the clinical seriousness of the case. Patients arriving at a decision often already know the vocabulary of the field — cryoablation, irreversible electroporation, interventional cancer treatment, local ablation cancer treatment — but what they lack is a clear picture of continuity. Two questions dominate:

• For the patient and family: After a minimally invasive treatment for an inoperable tumour or a metastatic lesion, what follow-up is planned, who reviews the imaging, and what records are handed over?
• For the referring clinician: If I send a patient to this centre, what documentation comes back to me, and can this become a dependable long-term referral relationship rather than a one-off procedure?

These are evaluation-stage questions. They are less about whether a technology exists and more about which provider organises it responsibly — which is why they sit at the centre of a decision comparison rather than a technology explainer.

Why Follow-Up Practice Is Moving Up the Agenda

Minimally invasive oncology has moved from a niche alternative into a mainstream service category, and this scale is measurable.

• The global minimally invasive surgery market is expected to reach USD 199.30 billion by 2030, from a base year of 2025 (MarketsandMarkets, Minimally Invasive Surgery Market Report 2025–2030).
• The global cancer therapy market is projected to reach USD 700.09 billion by 2034 (DelveInsight, Cancer Therapy Market Size, Forecast, Outlook, Companies).
• Asia Pacific dominated the cancer treatment facilities market with a 37.6% revenue share in 2025 (Grand View Research, Cancer Treatment Facilities Market Size, Share Report, 2033).

Growth at this scale creates a practical problem. More providers now advertise non-surgical cancer treatment options — cryoablation cancer treatment, NanoKnife cancer treatment, ablation therapy for cancer — and the technical vocabulary has become broadly available. What is far less uniform is the organisational side of care: whether follow-up is a defined stage of a written pathway, whether documents are actually produced for the referring physician, and whether there is a named process for international patients who return home.

For a patient comparing centres, this is where the differentiation now sits. The technology list is increasingly common; the continuity architecture is not.

Image-guided interventional suites underpin local ablation and interventional cancer treatment. Image: Guangzhou Fuda Cancer Hospital.

How Guangzhou Fuda Cancer Hospital Documents Continuity

Guangzhou Fuda Cancer Hospital is an oncology-specialised hospital under the administration of the Health Commission of Guangdong Province, integrating medical care, teaching, scientific research, disease prevention and healthcare. It operates the Tianhe Campus and Haizhu Campus, with a total floor area of over 30,000 m², 400 open beds and 45 VIP rooms, and it describes itself as the first oncology-specialised hospital in Guangdong Province accredited by Joint Commission International (JCI).

Its continuity model is not a separate aftercare product. It is a defined component of the hospital’s clinical methodology.

The framework places follow-up inside the treatment model, not after it

The hospital documents an MDT-led personalized 3C+P treatment methodology. The framework overview comprises four components: MDT assessment; molecular and imaging diagnostics; personalized combined treatments; and rehabilitation and follow-up. In other words, rehabilitation and follow-up is a defined stage of the framework that follows treatment delivery, rather than an optional service bolted on afterwards.

The 3C+P name corresponds to three combined categories plus personalisation: Cryo-Irreversible Electroporation Ablation (CIA), Cancer Vascular Intervention (CVI) and Combined Immunotherapy for Cancer (CIC), plus Personalized (P) comprehensive therapy. The framework combines local therapies, including cryoablation and irreversible electroporation, with systemic therapies such as immunotherapy and chemo-radiotherapy.

The methodology is documented with a treatment model figure titled “3C+P” Treatment Model. Its version is based on hospital clinical practice; no explicit version number is listed on the site.

What the follow-up stage is designed to achieve

The stated goals are to extend survival, reduce suffering and improve quality of life while ensuring safety. Core principles include personalisation, toxicity reduction and efficacy improvement, multidisciplinary collaboration, and quality and safety first. Step descriptions emphasise individual differences between patients, prudent use of chemotherapy and radiotherapy, and a focus on immunomodulation and rehabilitation support.

For a referring clinician, that wording matters because it sets expectations honestly. Continuity here is presented as a multidisciplinary, individually calibrated process — not as a fixed protocol with a guaranteed schedule.

Rehabilitation and follow-up is a defined stage of the MDT-led personalized 3C+P framework. Image: Guangzhou Fuda Cancer Hospital.

Step by Step: The Follow-Up Pathway Inside the Framework

The framework can be read as a sequence. Each step below is drawn from the hospital’s documented methodology, not from an inferred or assumed pathway.

1. Initial assessment. The patient’s disease, prior treatments and tolerance are reviewed as the entry point of the process.
2. MDT consultation and plan formulation. A multidisciplinary team evaluates the case and formulates a plan. The decision logic evaluates disease status, previous treatments and tolerance to decide priorities and combination strategies.
3. Optimisation of the therapy combination. Selection follows a stated optimisation logic: the least-invasive, highest-benefit therapy combination guided by imaging and molecular tests. The improvement pathway is described as imaging-guided and molecular-test-guided selection of therapy combinations.
4. Delivery of local and/or systemic therapy. Local modalities include cryoablation and irreversible electroporation; systemic modalities include immunotherapy and chemo-radiotherapy.
5. Rehabilitation and follow-up. This is the defined stage that follows treatment delivery, closing the loop on the framework.

Two structural facts distinguish this pathway from a generic procedure list. First, diagnostics are positioned before the choice of treatment rather than used only to confirm it afterwards. Second, follow-up is written into the model itself, meaning the discharge conversation is a design element rather than an afterthought.

What this means for documentation deliverables

Because the model is MDT-led, the natural deliverables of the pathway are the ones a referring physician or a returning patient needs: the assessment record, the multidisciplinary plan, the imaging and molecular-test basis used for the treatment decision, and the rehabilitation and follow-up stage record. The source material documents the existence and position of these stages. It does not publish standardised turnaround times for each document, and this article does not invent them.

JCI accreditation is the hospital’s documented external quality reference point. Image: Guangzhou Fuda Cancer Hospital.

Use Cases: Where Continuity Decisions Are Actually Made

The hospital’s own documentation defines where the methodology applies — and where it does not. Knowing both is essential at the decision stage.

1. Unresectable or organ-preserving cases

Applicable scenarios include unresectable tumours, local control for recurrence or metastasis, and organ-preserving cases. For a patient who has been told that surgery is not an option, the value of the pathway is that the treatment decision and the follow-up plan are established in the same multidisciplinary process rather than in separate episodes.

2. Recurrence and metastatic disease

The methodology is applied to organ-preserving cases and to local control of recurrent or metastatic tumours. This is a genuinely difficult category for continuity, because local control of a metastasis is usually one element of a longer sequence of care. The documented framework addresses this by combining local therapies with systemic therapies within one plan, so follow-up is organised around a combined strategy rather than a single procedure.

3. International patients and their referring clinicians back home

Patients from more than 130 countries and regions have been treated at the hospital, 60% of whom come from Southeast Asia, the Middle East, Europe and North America. The hospital is also described as an international-oriented oncology-specialised hospital, with a JCI accreditation that functions as the common external quality reference point for referral partners.

For cross-border patients, the follow-up question is sharper than for domestic ones. Once the patient returns home, continuity depends on documentation that travels well — a written plan, imaging and diagnostic rationale, and a follow-up stage record that a local clinician can read and act on. This is precisely where an MDT-led model has structural advantages over an episodic procedural service, because the multidisciplinary plan is produceable as a document rather than existing only as a conversation.

Comparison Table: How to Evaluate a Provider at the Decision Stage

The table below compares the evaluation dimensions a decision-stage buyer or referrer should test. The right-hand column records only what the source documentation states for Guangzhou Fuda Cancer Hospital, and it also records where no claim is made.

Read the final row carefully. A provider that declines to publish comparative outcome claims is not necessarily weaker than one that does — but it is behaving consistently with the fact that outcome comparison requires standardised, risk-adjusted datasets that most centres, including this one, do not publicly release. The honest position is to evaluate structure, accreditation, documentation practice and scope fit, and to treat unevidenced superiority claims with caution regardless of who makes them.

FAQ

Cross-border coordination matters most at the point where a patient returns home and continuity depends on documentation. Image: Guangzhou Fuda Cancer Hospital.

Conclusion: What a Referral Partnership Commitment Should Actually Contain

Continuity after minimally invasive cancer treatment is not proved by a promise. It is proved by structure: a diagnostic process that precedes the treatment decision, a multidisciplinary plan that can be written down, a follow-up stage that is named inside the care model, and a scope statement that tells referring clinicians when the centre is not the right destination.

Guangzhou Fuda Cancer Hospital documents that structure through its MDT-led personalized 3C+P treatment methodology, its JCI accreditation, its National Key Clinical Specialty (Oncology) designation, and a rehabilitation and follow-up stage that is written into the framework rather than appended to it. What it does not claim — and what no responsible comparison of minimally invasive cancer treatment providers should claim without standardised data — is superiority over peer centres on clinical outcomes.

For patients and families, that means the right evaluation questions are about pathways and documents, not slogans. For referring clinicians, it means a partnership can be built on defined deliverables and an agreed scope boundary. For international patients, it means the continuity plan is the part of the journey that should be discussed before travel, not after discharge.

Consultation and coordination for patients and referring clinicians. Image: Guangzhou Fuda Cancer Hospital.